<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623544</url>
  </required_header>
  <id_info>
    <org_study_id>RWE-000015</org_study_id>
    <nct_id>NCT01623544</nct_id>
  </id_info>
  <brief_title>Asthma Comparative Effectiveness Study</brief_title>
  <acronym>Asthma CER</acronym>
  <official_title>A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone Propionate/Salmeterol Combination (FSC) Among Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the real-world effectiveness of BFC and FSC in
      asthma patients new to ICS/LABA combination therapy in a population of U.S. health plan
      enrollees.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A U.S. retrospective database analysis evaluating the comparative effectiveness of
      budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of asthma exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>The rate is defined as the total number of asthma exacerbations for all patients in the cohort divided by the total number of person years. An asthma exacerbation is defined as any of three conditions: Asthma related inpatient hospitalization or Asthma related emergency department visit or Oral corticosteroid use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Related Inpatient Hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Related Emergency Department visits</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of Oral Corticosteroids (OCS)</measure>
    <time_frame>12 months</time_frame>
    <description>A pharmacy claim for any of the OCS medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma controller medication use (SABA, ICS, LABA, LTRA, XOLAIR, THEOPHYLLINE)</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma controller use (0 vs. 1 and total number of fills for each).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Related Healthcare Utilization</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma Related Healthcare Utilization: Outpatient/office visits, Inpatient length of stay, ICU admission and length of stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Related Healthcare costs</measure>
    <time_frame>12 months</time_frame>
    <description>Asthma Related Healthcare costs (plan paid, patient paid and plan + patient paid)costs of all Asthma related medication and Asthma related outpatient/office, ED and Inpatient visits.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6086</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort</arm_group_label>
    <description>BFC patients new to ICS/LABA combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advair</arm_group_label>
    <description>FSC patients new to ICS/LABA combination therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Health plan members with asthma aged 12 to 64 years receiving two or more prescriptions for
        BFC or FSC during 6/1/2007-9/30/2010 who are naive to ICS/LABA combination therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Continuous health plan enrollment for 12 months before and after index Rx

          -  At least two prescription fills for BFC or FSC within 12 months

          -  Asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription

        Exclusion Criteria:

          -  Evidence of COPD

          -  Claims diagnosis of any of inflammatory diseases or cancer

          -  Presence of Rx for more than one type of ICS/LABA combination on index date

          -  Chronic steroid use or Xolair use prior to ICS/LABA index treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Comparative Effectiveness</keyword>
  <keyword>Symbicort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

